Identification of the Clinical Development Candidate MRTX849 , a Covalent KRASG12C Inhibitor for the Treatment of Cancer
Jay B. Fell, John P. Fischer, Brian R. Baer et al. · Journal of Medicinal Chemistry · 2020
Abstract Capping off an era marred by drug development failures and punctuated by waning interest and presumed intractability toward direct targeting of KRAS, new technologies and strategies are aiding in the target’s resurgence. As previously reported, the tetrahydropyridopyrimidines were identified as irreversible covalent inhibitors of KRASG12C that bind in the switch-II pocket of KRAS and make a covalent bond to cysteine 12. Using structure-based drug design in conjunction with a focused in vitro absorption, distribution, metabolism and excretion screening approach, analogues were synthesized to increase the potency and reduce metabolic liabilities of this series. The discovery of the clinical development candidate MRTX849 as a potent, selective covalent inhibitor of KRASG12C is described.
Cited by 615 works. doi:10.1021/acs.jmedchem.9b02052
Authors
- Jay B. Fell
- Brian R. Baer
- James F. Blake
- Karyn Bouhana
- David M. Briere
- Karin D. Brown
- Laurence E. Burgess
- Aaron C. Burns
- Michael Burkard
- Harrah Chiang
- Mark Joseph Chicarelli
- Adam W. Cook
- John J. Gaudino
- Jill F. Hallin
- Lauren M. Hanson
- Dylan P. Hartley
- Erik J. Hicken
- Gary P. Hingorani
- Ronald J. Hinklin
References
- ras oncogenes in human cancer: a review.
- Physiological Parameters in Laboratory Animals and Humans
- K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
- Oncogenic Signaling Pathways in The Cancer Genome Atlas
- The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
- RAS Proteins and Their Regulators in Human Disease
- Biochemical studies of toxic agents. 3. The isolation of 1- and 2-naphthylsulphuric acid and 1- and 2-naphthylglucuronide from the urine of rats dosed with 1- and 2-naphthol
- Kinetics of interaction of nucleotides with nucleotide-free H-ras p21
- The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
- Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor